Therapeutic benefit of polyamine‐modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Annals of Neurology

• Publication date

  2000-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/1531-8249(200012)48:6<943::AID-ANA18>3.0.CO;2-1PMID 11117554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis.

  1999cited by this paper
• Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase.

  1999cited by this paper
• Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood-brain barrier of putrescine-modified catalase in the adult rat.

  1999cited by this paper
• Superoxide dismutase and hydrogen peroxide cause rapid nitric oxide breakdown, peroxynitrite production and subsequent cell death.

  1999cited by this paper
• Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide.

  1998cited by this paper
• Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers.

  1997cited by this paper
• Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant.

  1997cited by this paper
• Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia.

  1997cited by this paper
• Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis

  1997cited by this paper
• Transgenic animal models of familial amyotrophic lateral sclerosis

  1997cited by this paper
• Polyamine Modification Increases the Permeability of Proteins at the Blood‐Nerve and Blood‐Brain Barriers

  1996cited by this paper
• Increased Permeability of Superoxide Dismutase at the Blood‐Nerve and Blood‐Brain Barriers with Retained Enzymatic Activity After Covalent Modification with the Naturally Occurring Polyamine, Putrescine

  1996cited by this paper
• Reversible binding and inhibition of catalase by nitric oxide.

  1995cited by this paper
• Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis.

  1995cited by this paper
• An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.

  1995cited by this paper
• Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

  1994cited by this paper
• Macromolecular permeability across the blood-nerve and blood-brain barriers.

  1994cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

  1993cited by this paper
• ALS, SOD and peroxynitrite

  1993cited by this paper
• Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

  1993cited by this paper
• Studies on ascorbic acid. II. Physical changes in catalase following incubation with ascorbate or ascorbate and copper (II).

  1967cited by this paper

• Brain Delivery of Protein Therapeutics by Cell Matrix‐Inspired Biomimetic Nanocarrier

  2024cites this paper
• Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles

  2021cites this paper
• Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies.

  2020cites this paper
• Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach

  2013cites this paper
• Amyotrophic Lateral Sclerosis Progress and Prospects for Treatment

  2012cites this paper
• Preclinical testing of potential therapeutics for Amyotrophic Lateral Sclerosis

  2012cites this paper
• Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis

  2012cites this paper
• Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases.

  2012cites this paper
• Vitamin D3 Deficiency Differentially Affects Functional and Disease Outcomes in the G93A Mouse Model of Amyotrophic Lateral Sclerosis

  2011cites this paper
• One Universal Common Endpoint in Mouse Models of Amyotrophic Lateral Sclerosis

  2011cites this paper
• Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis.

  2009cites this paper
• Mechanisms of potentiation of Angiotensin II-induced contractile response of isolated rat aorta by hydrogen peroxide and tert-butyryl hydroperoxide

  2009cites this paper
• Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

  2008cites this paper
• The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development.

  2008cites this paper
• CNS Delivery Via Adsorptive Transcytosis

  2008influential citation
• Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

  2008cites this paper
• Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

  2007cites this paper
• Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis.

  2007cites this paper
• Chapter 27 – Prevention and Therapy of Neurodegenerative Disorders: Role of Nutritional Antioxidants

  2007cites this paper
• Effects of peritoneal aluminum overload on polyamines and nitric oxide contents of testes and epididymis in the mice.

  2006cites this paper
• Role of Nutritional Antioxidants in the Prevention and Treatment of Neurodegenerative Disorders

  2006cites this paper
• Regulation of Neuroactive Metals by the Choroid Plexus

  2005cites this paper
• Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

  2004cites this paper
• Amyotrophic lateral sclerosis: progress and prospects for treatment.

  2003cites this paper
• Oxidative Stress in Familial Amyotrophic Lateral Sclerosis

  2003cites this paper
• Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid.

  2003cites this paper
• CEREBROSPINAL FLUID NITRITE AND MALONDIALDEHYDE LEVELS IN PATIENTS WITH MOTOR NEURON DISEASE

  2003cites this paper
• Chapter 10 Excitotoxicity and Oxidative Stress in Pathogenesis of Amyotrophic Lateral Sclerosis/Motor Neuron Disease

  2003cites this paper
• Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis

  2003cites this paper
• Therapeutic developments in the treatment of amyotrophic lateral sclerosis

  2002cites this paper
• Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.

  2002cites this paper
• Emerging strategies for drug development in motor neuron disease

  2002cites this paper
• Antioxidants as treatment for neurodegenerative disorders

  2002cites this paper
• A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes.

  2002cites this paper
• Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies.

  2002cites this paper
• Therapies in amyotrophic lateral sclerosis-beyond riluzole.

  2002cites this paper
• The Degradation of Amyloid β as a Therapeutic Strategy in Alzheimer's Disease and Cerebrovascular Amyloidoses

  2002cites this paper
• La cationisation, un procédé de vectorisation des anticorps dans le système nerveux central: Problèmes recontrés pour son application dans le cadre de stratégies d’immunothérapie comme celles des intoxications clostridiales

  2001cites this paper
• Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood–brain barrier

  2001cites this paper
• Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model.

  2001cites this paper
• Role of Free Radicals in the Neurodegenerative Diseases

  2001cites this paper
• Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier.

  2001cites this paper
• Towards gene therapy in amyotrophic lateral sclerosis

  2000cites this paper